Sunday, December 1 | 1:40 p.m.-1:50 a.m. | S4-SSPH02-5 | Room S404
In this session, audience members will learn about the sustainability of commercially available contrast-enhanced mammography (CEM) phantoms in quality control programs.
Emily Thompson, PhD, from the MD Anderson Cancer Center in Houston, TX, will present her team’s results, which show that both phantoms analyzed have utility in a routine quality control program for CEM.
Radiologists are exploring the potential of dual-energy CEM in improving the detection and characterization of breast lesions. However, the researchers noted that quality control procedures have not been well-defined. They highlighted that a quality control program would help standardize imaging protocols, assess image quality, verify contrast agent uptake, monitor system performance, and ensure quality assurance in clinical practice.
To test this, the team assessed two commercially available CEM phantoms: Contrast Enhanced Spectral Mammography Phantom Model 022 (CIRS, Virginia; phantom A) and the Mammo CESMΤΜ Phantom PN 805929 (Sun Nuclear, Wisconsin; phantom B). It tested the reproducibility of the phantoms across Hologic, GE HealthCare, and Siemens Healthineers mammography systems.
The researchers found that both phantoms could be used in a routine quality control program, which can help with maintaining CEM systems and delivering consistent diagnostic results. They can also be used to evaluate signal-to-noise ratio, contrast-to-noise ratio, reproducibility, breast texture cancellation, and iodine concentration at different breast thicknesses and tissue combinations.
The team further highlighted that while phantom A is well-suited for routine quality control performed by multiple people, phantom B allows for deeper analysis of smaller changes in tissue composition and iodine concentration. Find out what else the researchers found with these phantoms by attending this session.
